46
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      “It still affects our economic situation”: long-term economic burden of breast cancer and lymphedema

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Financial toxicity after breast cancer may be exacerbated by adverse treatment effects, like breast cancer-related lymphedema. As the first study of long-term out-of-pocket costs for breast cancer survivors in the USA with lymphedema, this mixed methods study compares out-of-pocket costs for breast cancer survivors with and without lymphedema.

          Methods

          In 2015, 129 breast cancer survivors from Pennsylvania and New Jersey completed surveys on demographics, economically burdensome events since cancer diagnosis, cancer treatment factors, insurance, and comorbidities; and prospective monthly out-of-pocket cost diaries over 12 months. Forty participants completed in-person semi-structured interviews. GLM regression predicted annual dollar amount estimates.

          Results

          46.5% of participants had lymphedema. Mean age was 63 years (SD = 8). Average time since cancer diagnosis was 12 years (SD = 5). Over 98% had insurance. Annual adjusted health-related out-of-pocket costs excluding productivity losses totaled $2306 compared to $1090 ( p = 0.006) for those without lymphedema, or including productivity losses, $3325 compared to $2792 ( p = 0.55). Interviews suggested that the cascading nature of economic burden on long-term savings and work opportunities, and insufficiency of insurance to cover lymphedema-related needs drove cost differences. Higher costs delayed retirement, reduced employment, and increased inability to access lymphedema care.

          Conclusions

          Long-term cancer survivors with lymphedema may face up to 112% higher out-of-pocket costs than those without lymphedema, which influences lymphedema management, and has lasting impact on savings and productivity. Findings reinforce the need for actions at policy, provider, and individual patient levels, to reduce lymphedema costs. Future work should explore patient-driven recommendations to reduce economic burden after cancer.

          Electronic supplementary material

          The online version of this article (10.1007/s00520-018-4418-4) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.

          Cancer patients carry rising burdens of health care-related out-of-pocket expenses, and a growing number of patients are considered "underinsured." Our objective was to describe experiences of insured cancer patients requesting copayment assistance and to describe the impact of health care expenses on well-being and treatment. We conducted baseline and follow-up surveys regarding the impact of health care costs on well-being and treatment among cancer patients who contacted a national copayment assistance foundation along with a comparison sample of patients treated at an academic medical center. Among 254 participants, 75% applied for drug copayment assistance. Forty-two percent of participants reported a significant or catastrophic subjective financial burden; 68% cut back on leisure activities, 46% reduced spending on food and clothing, and 46% used savings to defray out-of-pocket expenses. To save money, 20% took less than the prescribed amount of medication, 19% partially filled prescriptions, and 24% avoided filling prescriptions altogether. Copayment assistance applicants were more likely than nonapplicants to employ at least one of these strategies to defray costs (98% vs. 78%). In an adjusted analysis, younger age, larger household size, applying for copayment assistance, and communicating with physicians about costs were associated with greater subjective financial burden. Insured patients undergoing cancer treatment and seeking copayment assistance experience considerable subjective financial burden, and they may alter their care to defray out-of-pocket expenses. Health insurance does not eliminate financial distress or health disparities among cancer patients. Future research should investigate coverage thresholds that minimize adverse financial outcomes and identify cancer patients at greatest risk for financial toxicity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis.

            Much has been written about the relationship between high medical expenses and the likelihood of filing for bankruptcy, but the relationship between receiving a cancer diagnosis and filing for bankruptcy is less well understood. We estimated the incidence and relative risk of bankruptcy for people age twenty-one or older diagnosed with cancer compared to people the same age without cancer by conducting a retrospective cohort analysis that used a variety of medical, personal, legal, and bankruptcy sources covering the Western District of Washington State in US Bankruptcy Court for the period 1995-2009. We found that cancer patients were 2.65 times more likely to go bankrupt than people without cancer. Younger cancer patients had 2-5 times higher rates of bankruptcy than cancer patients age sixty-five or older, which indicates that Medicare and Social Security may mitigate bankruptcy risk for the older group. The findings suggest that employers and governments may have a policy role to play in creating programs and incentives that could help people cover expenses in the first year following a cancer diagnosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Financial Toxicity of Cancer Care: It's Time to Intervene.

              S Zafar (2016)
              Evidence suggests that a considerably large proportion of cancer patients are affected by treatment-related financial harm. As medical debt grows for some with cancer, the downstream effects can be catastrophic, with a recent study suggesting a link between extreme financial distress and worse mortality. At least three factors might explain the relationship between extreme financial distress and greater risk of mortality: 1) overall poorer well-being, 2) impaired health-related quality of life, and 3) sub-par quality of care. While research has described the financial harm associated with cancer treatment, little has been done to effectively intervene on the problem. Long-term solutions must focus on policy changes to reduce unsustainable drug prices and promote innovative insurance models. In the mean time, patients continue to struggle with high out-of-pocket costs. For more immediate solutions, we should look to the oncologist and patient. Oncologists should focus on the value of care delivered, encourage patient engagement on the topic of costs, and be better educated on financial resources available to patients. For their part, patients need improved cost-related health literacy so they are aware of potential costs and resources, and research should focus on how patients define high-value care. With a growing list of financial side effects induced by cancer treatment, the time has come to intervene on the "financial toxicity" of cancer care.
                Bookmark

                Author and article information

                Contributors
                410.502.7205 , ldean9@jhu.edu
                Journal
                Support Care Cancer
                Support Care Cancer
                Supportive Care in Cancer
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0941-4355
                1433-7339
                18 August 2018
                18 August 2018
                2019
                : 27
                : 5
                : 1697-1708
                Affiliations
                [1 ]ISNI 0000 0001 2171 9311, GRID grid.21107.35, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, , Johns Hopkins University, ; 615 N Wolfe St, E6650, Baltimore, MD 21205 USA
                [2 ]ISNI 0000 0001 2171 9311, GRID grid.21107.35, Department of Oncology, , Johns Hopkins School of Medicine, ; Baltimore, MD USA
                [3 ]ISNI 0000000419368729, GRID grid.21729.3f, Department of Epidemiology, Mailman School of Public Health, , Columbia University, ; New York, NY USA
                [4 ]ISNI 0000000419368710, GRID grid.47100.32, Department of Social & Behavioral Sciences, , Yale School of Public Health, ; New Haven, CT USA
                [5 ]ISNI 0000 0001 2171 9311, GRID grid.21107.35, Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, , Johns Hopkins University, ; Baltimore, MD USA
                [6 ]ISNI 0000 0004 1936 8972, GRID grid.25879.31, Department of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, , University of Pennsylvania, ; Philadelphia, PA USA
                [7 ]ISNI 0000 0001 2097 4281, GRID grid.29857.31, Department of Public Health Sciences, Pennsylvania State University College of Medicine, , Pennsylvania State University, ; Hershey, PA USA
                Author information
                http://orcid.org/0000-0002-2272-2755
                Article
                4418
                10.1007/s00520-018-4418-4
                6379148
                30121786
                e087d603-10a3-463e-ac11-bd9fb6af13d5
                © The Author(s) 2018

                Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 20 November 2017
                : 9 August 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100006108, National Center for Advancing Translational Sciences;
                Award ID: 1UL1TR001079
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000025, National Institute of Mental Health;
                Award ID: R25MH083620
                Award ID: K01MH111374
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000054, National Cancer Institute;
                Award ID: K01CA184288
                Award ID: P30CA006973
                Award ID: P30CA006973
                Award ID: R01CA106851
                Award ID: 1U54CA155850
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: P30AI094189
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000049, National Institute on Aging;
                Award ID: K01AG04176
                Award Recipient :
                Funded by: National Institute on Drug Abuse
                Award ID: T32DA031099
                Award Recipient :
                Categories
                Original Article
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2019

                Oncology & Radiotherapy
                breast cancer,lymphedema,financial toxicity,economic burden
                Oncology & Radiotherapy
                breast cancer, lymphedema, financial toxicity, economic burden

                Comments

                Comment on this article